- Home
- LUCY vs OGEN Comparison
LUCY vs OGEN Comparison
Compare LUCY & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCY
- OGEN
- Stock Information
- Founded
- LUCY 2017
- OGEN 1996
- Country
- LUCY United States
- OGEN United States
- Employees
- LUCY N/A
- OGEN N/A
- Industry
- LUCY Ophthalmic Goods
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- LUCY Health Care
- OGEN Health Care
- Exchange
- LUCY Nasdaq
- OGEN Nasdaq
- Market Cap
- LUCY 18.5M
- OGEN 4.5M
- IPO Year
- LUCY 2022
- OGEN N/A
- Fundamental
- Price
- LUCY $6.90
- OGEN $0.34
- Analyst Decision
- LUCY Strong Buy
- OGEN
- Analyst Count
- LUCY 1
- OGEN 0
- Target Price
- LUCY $20.00
- OGEN N/A
- AVG Volume (30 Days)
- LUCY 104.1K
- OGEN 389.1K
- Earning Date
- LUCY 11-12-2024
- OGEN 11-07-2024
- Dividend Yield
- LUCY N/A
- OGEN N/A
- EPS Growth
- LUCY N/A
- OGEN N/A
- EPS
- LUCY N/A
- OGEN N/A
- Revenue
- LUCY $1,529,782.00
- OGEN $7,466.00
- Revenue This Year
- LUCY $245.17
- OGEN N/A
- Revenue Next Year
- LUCY $258.97
- OGEN N/A
- P/E Ratio
- LUCY N/A
- OGEN N/A
- Revenue Growth
- LUCY 186.54
- OGEN N/A
- 52 Week Low
- LUCY $3.26
- OGEN $0.29
- 52 Week High
- LUCY $27.20
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- LUCY 44.95
- OGEN 37.15
- Support Level
- LUCY $6.33
- OGEN $0.29
- Resistance Level
- LUCY $6.89
- OGEN $0.45
- Average True Range (ATR)
- LUCY 0.59
- OGEN 0.04
- MACD
- LUCY -0.27
- OGEN 0.02
- Stochastic Oscillator
- LUCY 14.46
- OGEN 28.88
About LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands free.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.